Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Lianxin Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3535-6467; OpenAlex author ID A5019223769, A5136469820. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 7

  1. ABHD17C-Mediated S-Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer. Last author DOI 10.1002/advs.75757↗
  2. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  3. Ultrahigh Enzyme Loading Metal-Organic Frameworks for Deep Tissue Pancreatic Cancer Photoimmunotherapy. Co-author DOI 10.1002/smll.202305131↗
  4. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  5. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis. Last author DOI 10.1158/1078-0432.ccr-18-4113↗
  6. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  7. Analysis of 300 consecutive cases of pancreatic adenocarcinoma in a single-center in China. Co-author DOI 10.1016/s1499-3872(16)60066-8↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiushi Lin · 3 shared papers, 2019–2026 · strength 0.38
  2. Xuewei Bai · 3 shared papers, 2019–2026 · strength 0.38
  3. Rui Kong · 3 shared papers, 2019–2026 · strength 0.38
  4. Katsuya Nagaoka · 3 shared papers, 2019–2026 · strength 0.38
  5. Xiaoqun Dong · 3 shared papers, 2019–2026 · strength 0.38
  6. Jack R. Wands · 3 shared papers, 2019–2026 · strength 0.38
  7. Kosuke Ogawa · 3 shared papers, 2019–2026 · strength 0.38
  8. Le Li · 3 shared papers, 2019–2026 · strength 0.38
  9. Howard P. Safran · 3 shared papers, 2019–2026 · strength 0.38
  10. Min Li · 2 shared papers, 2019–2026 · strength 0.30
  11. Yalu Zhang · 1 shared paper, 2026 · strength 0.29
  12. Yongwei Wang · 1 shared paper, 2026 · strength 0.22
  13. Yucai Wang · 1 shared paper, 2024 · strength 0.22
  14. Qian Liu · 1 shared paper, 2024 · strength 0.22
  15. Li Wang · 1 shared paper, 2024 · strength 0.22
  16. Yongwei Wang · 2 shared papers, 2019–2020 · strength 0.16
  17. Min Li · 2 shared papers, 2019–2020 · strength 0.15
  18. Bei Sun · 2 shared papers, 2016–2020 · strength 0.15
  19. Bei Sun · 1 shared paper, 2019 · strength 0.07
  20. Dehai Wu · 1 shared paper, 2019 · strength 0.06
  21. Yao Liu · 1 shared paper, 2019 · strength 0.06
  22. Dalong Yin · 1 shared paper, 2019 · strength 0.06
  23. Shangha Pan · 1 shared paper, 2019 · strength 0.06
  24. Tongsen Zheng · 1 shared paper, 2019 · strength 0.06
  25. Jingxuan Yang · 1 shared paper, 2019 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.